Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

Darron Brown, Kenneth Fife, Cosette M. Wheeler, Laura A. Koutsky, Lisa M. Lupinacci, Radha Railkar, Gretchen Suhr, Eliav Barr, Anthony Dicello, Weili Li, Judith F. Smith, Amha Tadesse, Kathrin U. Jansen

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.

Original languageEnglish
Pages (from-to)2936-2942
Number of pages7
JournalVaccine
Volume22
Issue number21-22
DOIs
StatePublished - Jul 29 2004

Fingerprint

Virus-Like Particle Vaccines
virus-like particle vaccines
Human papillomavirus 16
Papillomaviridae
Vaccines
Infection
infection
vaccines
Human papillomavirus 11
risk reduction
placebos
Vaccination
polymerase chain reaction
vaccination
Placebos
immune response
incidence
Polymerase Chain Reaction
Control Groups
Incidence

Keywords

  • Human papillomavirus
  • Polymerase chain reaction
  • Vaccination
  • Virus-like particle

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Brown, D., Fife, K., Wheeler, C. M., Koutsky, L. A., Lupinacci, L. M., Railkar, R., ... Jansen, K. U. (2004). Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine, 22(21-22), 2936-2942. https://doi.org/10.1016/j.vaccine.2003.11.059

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. / Brown, Darron; Fife, Kenneth; Wheeler, Cosette M.; Koutsky, Laura A.; Lupinacci, Lisa M.; Railkar, Radha; Suhr, Gretchen; Barr, Eliav; Dicello, Anthony; Li, Weili; Smith, Judith F.; Tadesse, Amha; Jansen, Kathrin U.

In: Vaccine, Vol. 22, No. 21-22, 29.07.2004, p. 2936-2942.

Research output: Contribution to journalArticle

Brown, D, Fife, K, Wheeler, CM, Koutsky, LA, Lupinacci, LM, Railkar, R, Suhr, G, Barr, E, Dicello, A, Li, W, Smith, JF, Tadesse, A & Jansen, KU 2004, 'Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine', Vaccine, vol. 22, no. 21-22, pp. 2936-2942. https://doi.org/10.1016/j.vaccine.2003.11.059
Brown, Darron ; Fife, Kenneth ; Wheeler, Cosette M. ; Koutsky, Laura A. ; Lupinacci, Lisa M. ; Railkar, Radha ; Suhr, Gretchen ; Barr, Eliav ; Dicello, Anthony ; Li, Weili ; Smith, Judith F. ; Tadesse, Amha ; Jansen, Kathrin U. / Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. In: Vaccine. 2004 ; Vol. 22, No. 21-22. pp. 2936-2942.
@article{e95e340c4c554f13815fe528654f985c,
title = "Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine",
abstract = "A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.",
keywords = "Human papillomavirus, Polymerase chain reaction, Vaccination, Virus-like particle",
author = "Darron Brown and Kenneth Fife and Wheeler, {Cosette M.} and Koutsky, {Laura A.} and Lupinacci, {Lisa M.} and Radha Railkar and Gretchen Suhr and Eliav Barr and Anthony Dicello and Weili Li and Smith, {Judith F.} and Amha Tadesse and Jansen, {Kathrin U.}",
year = "2004",
month = "7",
day = "29",
doi = "10.1016/j.vaccine.2003.11.059",
language = "English",
volume = "22",
pages = "2936--2942",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "21-22",

}

TY - JOUR

T1 - Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

AU - Brown, Darron

AU - Fife, Kenneth

AU - Wheeler, Cosette M.

AU - Koutsky, Laura A.

AU - Lupinacci, Lisa M.

AU - Railkar, Radha

AU - Suhr, Gretchen

AU - Barr, Eliav

AU - Dicello, Anthony

AU - Li, Weili

AU - Smith, Judith F.

AU - Tadesse, Amha

AU - Jansen, Kathrin U.

PY - 2004/7/29

Y1 - 2004/7/29

N2 - A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.

AB - A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was given at 0, 2 and 6 months. HPV16 infection was defined by positive polymerase chain reaction (PCR) results following vaccination. The incidence of HPV infection was observed to be 0 cases per 100 person-years at risk in the vaccine group, and 5 cases per 100 person-years at risk in the control group. These results support the institution of larger efficacy trials for HPV L1 VLP vaccines.

KW - Human papillomavirus

KW - Polymerase chain reaction

KW - Vaccination

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=3142568679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142568679&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2003.11.059

DO - 10.1016/j.vaccine.2003.11.059

M3 - Article

C2 - 15246630

AN - SCOPUS:3142568679

VL - 22

SP - 2936

EP - 2942

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 21-22

ER -